Viewing Study NCT02866903


Ignite Creation Date: 2025-12-24 @ 7:19 PM
Ignite Modification Date: 2026-02-17 @ 10:46 PM
Study NCT ID: NCT02866903
Status: UNKNOWN
Last Update Posted: 2017-09-21
First Post: 2016-08-04
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Safety of Intraperitoneal (IP) OXAliplatin (OXA) in Association With Systemic FOLFIRI Bevacizumab Chemotherapy in Patients With Peritoneal Carcinosis
Sponsor: Hospices Civils de Lyon
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Peritoneal Carcinosis View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Peritoneal carcinosis View
None intraperitoneal (IP) OXAliplatin View
None Phase I/II dose escalation trial View
None FOLFIRI Bevacizumab chemotherapy View